Anatomy of a Setback: A Taxonomy of Clinical Trial Failures in Alzheimer's Disease and Strategic Lessons for the Future
Open Access
- 20 August 2026
- journal article
- perspective
- Published by Wiley in The FASEB Journal
- Vol. 40 (16) , e72221
Abstract
Although Alzheimer's disease (AD) carries the highest clinical trial failure rate of any major therapeutic area, the strategic lessons from more than two decades of negative outcomes remain insufficiently integrated into drug development practice. To date, trial failures have been examined largely in isolation, with limited attention to the recurring patterns that may connect them across therapeutic classes and disease stages. In this perspective, we propose a taxonomy that assigns AD therapeutic failures to five categories according to the primary driver of each negative outcome—namely wrong target, wrong timing, wrong patient, insufficient target engagement, and wrong endpoint. We subsequently applied this framework to a representative set of drugs that entered clinical testing between 2000 and 2025, comprising anti‐amyloid monoclonal antibodies, β‐site amyloid precursor protein‐cleaving enzyme 1 inhibitors, tau‐directed immunotherapies, neuroimmune‐targeting agents, and metabolic repurposing candidates. Analysis across classes showed that the distribution of failure categories shifted progressively over time, from predominantly target‐related failures in the mid‐to‐late 2010s toward patient‐selection and endpoint‐related failures in the current decade. From these patterns, we formulated strategic recommendations for next‐generation trial design—including biomarker‐driven patient enrichment, mechanism‐specific endpoint validation, and adaptive platform architectures. Because numerous failures examined here replicate the negative outcomes of earlier programs, we conclude that a substantial proportion of late‐stage AD trial failures may be structurally predictable and, through systematic classification, at least in part preventable. Despite these promising findings, the proposed taxonomy should be considered a working heuristic requiring external calibration before prospective deployment.Keywords
This publication has 52 references indexed in Scilit:
- Assessing clinical meaningfulness in clinical trials for Alzheimer's disease: A U.S. regulatory perspectiveAlzheimer's & Dementia: Translational Research & Clinical Interventions, 2025
- Alzheimer's disease drug development pipeline: 2024Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2024
- Donanemab in Early Symptomatic Alzheimer DiseaseJAMA, 2023
- Expectations and clinical meaningfulness of randomized controlled trialsAlzheimer's & Dementia, 2023
- Exploratory evaluation of 18F‐MK‐6240 tau PET positivity in TANGO phase 2 clinical trial of gosuranemab (BIIB092) in Mild Cognitive Impairment and mild Alzheimer’s diseaseAlzheimer's & Dementia, 2022
- Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer DiseaseJAMA Neurology, 2022
- Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer DiseaseJAMA Neurology, 2021
- Baseline characteristics from TANGO: Phase 2 study to evaluate gosuranemab (BIIB092) in patients with early Alzheimer’s diseaseAlzheimer's & Dementia, 2020
- Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer DiseaseJAMA Neurology, 2020
- Composite neurocognitive endpoints in Alzheimer's disease clinical trials: A commentaryAlzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2020